ArticleEuropean heart journal. Case reports2026
Myocardial immune vulnerability unmasked after treatment with immune checkpoint inhibitors: a case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although uncommon (incidence <1%), cardiac immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy can be fatal. Their underlying mechanisms remain incompletely understood, although autoimmune predisposition and cross-antigen responses have been implicated. Case summary: We report the case of a young, immunologically predisposed patient with renal cell carcinoma who developed recurrent episodes of myocardial injury following an initial mild ICI-related myocarditis. Subsequent viral infections acted as triggers for repeated myocardial damage despite discontinuation of ICI therapy. Discussion: Novel immune biomarkers were identified, and distinctive findings on endomyocardial biopsy, together with tumour protein expression patterns, provided insight into the patient's heightened myocardial immune vulnerability to viral infections. This case highlights the complex interplay between ICI therapy, host immune predisposition, and viral triggers in the pathogenesis of cardiac irAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.